NASDAQ:AVNR - Avanir Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Receive AVNR News and Ratings via Email

Sign-up to receive the latest news and ratings for AVNR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:AVNR
Previous Symbol
CUSIP05348P40
Phone+1-949-3896700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Avanir Pharmaceuticals (NASDAQ:AVNR) Frequently Asked Questions

What is Avanir Pharmaceuticals' stock symbol?

Avanir Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVNR."

Has Avanir Pharmaceuticals been receiving favorable news coverage?

Headlines about AVNR stock have trended somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avanir Pharmaceuticals earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future.

How do I buy shares of Avanir Pharmaceuticals?

Shares of AVNR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avanir Pharmaceuticals' official website?

The official website for Avanir Pharmaceuticals is http://www.avanir.com/.

How can I contact Avanir Pharmaceuticals?

Avanir Pharmaceuticals' mailing address is 20 Enterprise Ste 200, ALISO VIEJO, CA 92656-7104, United States. The healthcare company can be reached via phone at +1-949-3896700.


MarketBeat Community Rating for Avanir Pharmaceuticals (NASDAQ AVNR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about Avanir Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVNR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVNR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel